• TPPU: A Soluble Epoxide Hydrolase Inhibitor

  2026-09-17

  TPPU is a potent soluble epoxide hydrolase inhibitor that increases fatty acid epoxide signaling by limiting EET hydrolysis. Its nanomolar human and mouse sEH activity supports inflammatory pain research, while emerging liver–bone findings define a research hypothesis rather than a clinical indication.

• Parthenolide, ROS, and Apoptosis in Lymphoid Malignancies

  2026-09-16

  This study integrated resazurin-based metabolic measurements with flow-cytometric and gene-expression analyses to show that parthenolide reduces viability and promotes oxidative-stress-associated apoptosis across diverse lymphoid malignancy models. Its main practical contribution is a comparative framework linking metabolic suppression to ROS accumulation, glutathione depletion, mitochondrial dysfunction, and cell-line-dependent signaling responses.

• mRNA-Loaded Dendritic Cells in Melanoma

  2026-09-16

  The reference study examined long-term outcomes after complete melanoma metastasis resection followed by autologous dendritic cells electroporated with multiple melanoma-antigen mRNAs. More than six years of follow-up supported the feasibility and tolerability of this adjuvant strategy, while the single-center, non-randomized design means that its encouraging survival estimates require controlled validation.

• Nigericin sodium salt: Practical Assay Guide

  2026-09-15

  Nigericin sodium salt (SKU B7644) is a potassium ionophore for controlled K⁺/H⁺ exchange, supporting studies of ion gradients, cytoplasmic pH, platelet responses, and Pb²⁺ transport. It is intended for research workflows only and should not be presented as a validated treatment for lead intoxication or as a universal reagent for every cell model.

• SR 11302 for AP-1-Driven Cancer Workflows

  2026-09-15

  SR 11302 enables selective AP-1 pathway interrogation across tumor-cell and macrophage assays without relying on retinoid receptor activation. This guide translates evidence from colitis-associated colorectal cancer research into practical dose-finding, reporter, qPCR, flow-cytometry, and troubleshooting workflows.

• Relative and Fractional Viability in Cancer Drug Testing

  2026-09-14

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated metrics capture different combinations of growth inhibition and cell death. Its central implication is practical: cancer drug studies should define the biological endpoint being measured and interpret proliferation arrest, killing, and response timing separately.

• Disodium bicinchoninate for Endothelial Assays

  2026-09-14

  Disodium bicinchoninate provides an aqueous route for protein normalization in endothelial stress workflows without a DMSO or ethanol vehicle. This guide translates an H2O2-induced HUVEC study into practical assay design, reagent preparation, quality controls, and troubleshooting steps for mechanistic cell biology.

• Iptacopan (LNP023): Complement Assay Workflows

  2026-09-13

  Iptacopan (LNP023) gives researchers a selective, reversible way to isolate alternative-pathway biology without broadly suppressing complement. This guide translates its factor B mechanism into practical hemolysis, C3 deposition, serum, and disease-model workflows, with optimization advice for reproducible complement activation research.

• Cyclic di-GMP: Biofilm and STING Workflows

  2026-09-12

  Cyclic di-GMP connects bacterial persistence biology with STING-focused immune modulation research. This practical guide translates its antitoxin and STING agonist roles into biofilm, biochemical, and cancer immunotherapy studies while emphasizing preparation, controls, and troubleshooting.

• Anti Reverse Cap Analog for High-Expression mRNA

  2026-09-11

  Anti Reverse Cap Analog, 3´-O-Me-m7G(5')ppp(5')G, gives in vitro transcription workflows orientation-specific Cap 0 mRNA with approximately twofold higher translation than conventional m7G capping. This article connects cap optimization with LNP delivery, including the IL-10 mRNA strategy used to study poststroke microglia and blood–brain barrier repair.

• Anti Reverse Cap Analog for Synthetic mRNA

  2026-09-11

  Anti Reverse Cap Analog (ARCA) enables orientation-controlled 5′ capping for high-expression synthetic mRNA workflows. Its value is especially clear in transient cell-fate programming, where reliable translation can improve repeated delivery strategies without genomic integration.

• DMXAA (Vadimezan) Workflow for Tumor Models

  2026-09-10

  DMXAA (Vadimezan) supports complementary tumor-cell, endothelial, enzymatic, and formulation-based assays. This workflow connects vascular disruption and VEGFR2-related signaling with a recent nuclear-targeted nanorod strategy that uses DMXAA to amplify DNA damage and STING-associated innate immunity.

• ARL4C and Macrophage Dynamics in Rheumatoid Arthritis

  2026-09-10

  The reference study integrates single-cell and bulk transcriptomics with cellular co-culture and collagen-induced arthritis experiments to position ARL4C as a regulator of aggressive fibroblast-like synoviocyte behavior in rheumatoid arthritis. Its findings connect ARL4C-dependent synoviocyte proliferation and invasion with macrophage polarization, while suggesting that local ARL4C silencing may help reduce inflammatory and cartilage-damaging phenotypes.

• Tofacitinib Citrate in Translational JAK Research

  2026-09-09

  Tofacitinib citrate is more than a JAK3-directed research reagent: used with concentration-aware immune and endothelial assays, it can reveal why cytokine suppression does not necessarily predict vascular protection.

• GPX4 and Platinum Resistance in Lung Cancer Brain Metastasis

  2026-09-09

  Liu and colleagues identified a glutathione-consuming, ferroptosis-suppressive program that gives lung cancer-derived brain metastatic cells acquired resistance to platinum drugs. Their integrated model places Wnt/NR2F2-dependent GPX4 transcription upstream of this metabolic adaptation, suggesting that GPX4-directed interventions could improve platinum responses while highlighting the need for brain-metastasis-specific validation.

8521 records 1/569 page Next 12345 下5页 Last page